Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study
Markus Joerger(Kantonsspital St. Gallen), Thomas Cerny(University of Bern), Stefan Diem(University of St.Gallen), C. Schaer-Thuer(University of St.Gallen), Klazien Matter‐Walstra(University of Basel), Dieter Koeberle(Kantonsspital St. Gallen), Beat Thuerlimann(Kantonsspital St. Gallen), J. Gibbons-Marsico(University of St.Gallen)
Cited by 28
Related Papers
Comparison of Orally Administered Cannabis Extract and Delta-9-Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group
|Journal of Clinical Oncology|2006|409
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
|Annals of Oncology|2019|244
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer
|British Journal of Cancer|1996|220
Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group
|Journal of Clinical Oncology|2011|190
Expression of epidermal growth factor receptor (EGF-R) in human lung tumours
|British Journal of Cancer|1986|144